“ADR is a cornerstone quality indicator in colonoscopies, and bowel preparation quality directly affects colonoscopy performance and ADR,” explained Dr Besim Agargun (University of Istanbul, Turkey) [1]. “NLP of free-text colonoscopy reports could enable automated extraction of colonoscopy quality indicators.” The retrospective study aimed to develop a rule-based NLP model to assess bowel preparation quality. In total, 11,374 colonoscopy reports were analysed, of which 1,018 were used for training purposes. The model incorporated parameters such as caecal intubation, polyp presence, size, and location.
The model achieved a cross-validated accuracy of 92%. The precision and recall were 0.98/0.99 for good, 0.85/0.82 for intermediate, and 0.85/0.87 for poor bowel preparation. The predicted distribution was 50.9% good, 19.1% intermediate, and 30.0% poor bowel preparations. “The model showed robust and reproducible performance in real-world free-text reports,” said Dr Agargun. Older age, male sex, successful caecal intubation, and better bowel cleanliness were all associated with an increased ADR (see Figure).
Figure: Factors associated with adenoma detection rate [1]

“This study demonstrates that NLP-based automated classification of bowel preparation quality is both feasible and valuable for generating colonoscopy datasets to support quality monitoring,” concluded Dr Agargun. “By assessing bowel cleanliness alongside other ADR-related factors, such as age, sex, and caecal intubation, benchmarks for ADR can be established and applied to quality control and improvement in endoscopy centres.”
- Agargun BF, et al. NLP-based classification of bowel preparation quality and its association with ADR in colonoscopy reports. LB20, Latest News: From top to bottom, UEG Week, 4–7 October 2025, Berlin, Germany.
Posted on
Previous Article
« Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis? Next Article
Extended surveillance intervals after colorectal ESD may be safe and feasible »
« Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis? Next Article
Extended surveillance intervals after colorectal ESD may be safe and feasible »
Table of Contents: UEGW 2025
Featured articles
Mufemilast advances to phase 3 following positive phase 2 results in UC
Malignancies and Related Topics
Early detection of pancreatic cancer with an AI tool may save lives
Endoscopic approach preferred over surgery in gastric outlet syndrome
Reducing TME burden with a risk-stratified approach in early rectal cancer
PuraStat is effective and safe in real-world radiation proctopathy
Extended surveillance intervals after colorectal ESD may be safe and feasible
A machine learning model to improve bowel preparation quality monitoring
Can vedolizumab simplify the management of checkpoint inhibitor-induced enterocolitis?
Risk-stratified screening for CRC is more effective at the same spending rate
Highlights in Hepatology
Sugar-sweetened and non-sugar–sweetened beverages linked to MASLD risk
GLISTEN: Linerixibat meets primary endpoint in PBC-associated cholestatic pruritus
Even limited alcohol consumption is linked to increased MASLD risk
GLP-1 agonists in MASH: State-of-affairs
Diverse Top Research From UEG Week
Rabeprazole may be the preferred high-dose PPI in severe eGERD
Promising signs from a novel Helicobacter Pylori vaccine
Improving prevention and sustainability go hand-in-hand in IBD care
TRIASSIC: ESD superior to TAMIS for resection of non-pedunculated rectal lesions
Promising novel treatment option for functional dyspepsia
Latest Advancements in IBD
Intake of specific fibre subtypes linked to reduced risk of CD onset
Prospective insight into dietary patterns and relapse risk in IBD
Mufemilast advances to phase 3 following positive phase 2 results in UC
High-dose obefazimod is efficacious in UC regardless of prior therapy exposure
Can SIK3 inhibition become the Holy Grail for autoimmune diseases?
Relapse rate and risk factors after anti-TNF withdrawal in UC
TURN2: Well-prepared FMT shows efficacy in UC
Different outcomes of AI-read versus human-read endoscopies in the TITRATE study
Treatment efficacy of 7 therapies in perianal fistulising CD
ASTRO: Subcutaneous guselkumab maintains efficacy in UC through 2 years of follow-up
ANTHEM-UC: Oral IL-23 inhibitor delivers encouraging phase 2 data
Related Articles
April 8, 2025
Long-term use of etrasimod in UC safe and well-tolerated
October 23, 2019
Half of common medications wreak havoc on gut microbiome
August 9, 2019
Haematopoietic stem cells can sense tissue damage in the gut
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
